pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PADCEV · news · pharmadog
← back to PADCEV
News mentioning PADCEV
14
stories
6d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
15d
Pfizer flat in Q3 despite 32% growth for new and acquired products
biospace
16d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
25d
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
endpoints
Aug 6, 26
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
Aug 5, 26
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
Aug 4, 26
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
Jul 21, 26
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
Jul 13, 26
Agenus surges on study pivot; Apnimed lines up an IPO
biopharma dive
Jul 13, 26
Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial
endpoints
May 15, 26
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
biopharma dive
May 14, 26
AstraZeneca follows Merck with Phase 3 win in bladder cancer
endpoints
May 12, 26
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
onclive
May 6, 26
Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
onclive